Journal retracts study tied to Micronoma’s effort to create cancer blood test
By Angus Chen June 26, 2024
Reprints
Illustration of gram-positive Streptococcus pneumoniae bacteria.Dan Higgins/CDCNature retracted a high-profile paper that served as part of the scientific groundwork for Micronoma, a San Diego-based startup, on Wednesday.
“Some of the findings of the article are affected and the corresponding conclusions are no longer supported,” Nature said in the retraction.
advertisement
The retraction comes after a team of researchers published work on the preprint site bioRxiv critiquing the Nature paper last August, describing what they called “fatal errors” in the paper’s analyses. STAT covered the criticism shortly after the team’s manuscript went live on bioRxiv. This same work was later published in the peer-reviewed journal mBio.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribersUnlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.Already have an account? Log in
Monthly
$39
Totals $468 per year
$39/monthGet StartedTotals $468 per year
Starter
$20
for 3 months, then $399/year
$20 for 3 monthsGet StartedThen $399/year
Annual
$399
Save 15%
$399/yearGet StartedSave 15%
11+ Users
Custom
Savings start at 25%!
Request A QuoteRequest A QuoteSavings start at 25%!
2-10 Users
$300
Annually per user
$300/yearGet Started$300 Annually per user
View All PlansTo read the rest of this story subscribe to STAT+.
SubscribeLog InAbout the AuthorReprintsAngus ChenCancer Reporter
Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His work has been recognized by national Edward R. Murrow awards, the June L. Biedler prize for cancer journalism, and more.
[email protected]@angrchenTagsbiotechnology
Cancer
diagnostics
research
STAT+
To submit a correction request, please visit our Contact Us page.